ES2093078T3 - Compuesto farmaceuticamente activo sobre el snc. - Google Patents

Compuesto farmaceuticamente activo sobre el snc.

Info

Publication number
ES2093078T3
ES2093078T3 ES91304935T ES91304935T ES2093078T3 ES 2093078 T3 ES2093078 T3 ES 2093078T3 ES 91304935 T ES91304935 T ES 91304935T ES 91304935 T ES91304935 T ES 91304935T ES 2093078 T3 ES2093078 T3 ES 2093078T3
Authority
ES
Spain
Prior art keywords
elevated
hydrogen
halo
cns
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91304935T
Other languages
English (en)
Inventor
Michael John Leach
Malcolm Stuart Nobbs
Ramachandran Iyer
Clive Leonard Yeates
Philip Alan Skone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2093078T3 publication Critical patent/ES2093078T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicinal Preparation (AREA)
  • Paper (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION PRESENTA UNA SERIE DE COMPUESTOS QUE TIENEN LA FORMULA (I) Y SALES DEL MISMO, EN DONDE POR EJEMPLO, R ELEVADO 1 Y R (AL CUADRADO) , QUE PUEDEN SER IGUALES O DIFERENTES REPRESENTA CADA UNO-NR ELEVADO 13 R ELEVADO 14 DONDE R ELEVADO 13 Y R ELEVADO 14 PUEDEN REPRESENTAR CADA UNO INDEPENDIENTEMENTE HIDROGENO O ALQUILO, O SI SE TOMAN JUNTO CON EL ATOMO DE NITROGENO AL QUE ESTAN UNIDOS FORMAN UN ANILLO HEROSOCICLICO, OPCIONALMENTE SUSTITUIDO POR UNO O MAS GRUPOS DE ALQUILO O DE ARIALQUILO Y OPCIONALMENTE CONTIENEN UN HETEROATOMO ADICIONAL; R ELEVADO 3 ES HIDROGENO, HALOALQUILO, ALCOXIMETILO O ALQUILO; R ELEVADO 4 ES HIDROGENO, NITRO O HALO; R ELEVADO 5 ES HIDROGENO O HALO; R ELEVADO 6 ES HIDROGENO, HALO, NITRO, AMINO, ALQUILAMINO O DIALQUILAMINO; R ELEVADO 7 ES HIDROGENO O HALO; R ELEVADO 8 ES HIDROGENO O HALO; LOS COMPUESTOS PUEDEN SER UTILIZADOS PARA EL TRATAMIENTO O PROFILAXIS DE UN DESAJUSTE NEURODEGENERATIVO U OTRO NEUROLOGICO DEL SNC, LA ETIOLOGIA O QUE INCLUYE UNA DESCARGA EXCESIVA DE LA GLUTAMATA NEUROTRANSMISORA.
ES91304935T 1990-06-01 1991-05-31 Compuesto farmaceuticamente activo sobre el snc. Expired - Lifetime ES2093078T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012316A GB9012316D0 (en) 1990-06-01 1990-06-01 Pharmacologically active cns compounds

Publications (1)

Publication Number Publication Date
ES2093078T3 true ES2093078T3 (es) 1996-12-16

Family

ID=10676964

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91304935T Expired - Lifetime ES2093078T3 (es) 1990-06-01 1991-05-31 Compuesto farmaceuticamente activo sobre el snc.

Country Status (25)

Country Link
EP (2) EP0679645A1 (es)
JP (1) JPH06340634A (es)
KR (1) KR920000733A (es)
AT (1) ATE141263T1 (es)
AU (2) AU652753B2 (es)
CA (1) CA2043640A1 (es)
CZ (1) CZ281070B6 (es)
DE (1) DE69121317T2 (es)
DK (1) DK0459819T3 (es)
ES (1) ES2093078T3 (es)
FI (1) FI912623A7 (es)
GB (1) GB9012316D0 (es)
GR (1) GR3021237T3 (es)
HU (2) HUT58707A (es)
IE (1) IE911861A1 (es)
IL (2) IL113599A (es)
MY (2) MY136248A (es)
NO (1) NO180375C (es)
NZ (3) NZ238360A (es)
PL (2) PL166656B1 (es)
PT (1) PT97827B (es)
RU (1) RU2091374C1 (es)
SK (1) SK278444B6 (es)
TW (1) TW224460B (es)
ZA (1) ZA914165B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
ES2089498T3 (es) * 1991-01-30 1996-10-01 Wellcome Found Comprimidos dispersables en agua.
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
AU5704594A (en) * 1992-12-18 1994-07-19 Wellcome Foundation Limited, The Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9319341D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Novel process
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
TR200200701T2 (tr) 1999-09-16 2002-06-21 Tanabe Seiyaku Co., Ltd. Altı-elementli aromatik nitrojenli halka bileşimleri.
HRP20020673A2 (en) * 2000-02-25 2004-12-31 Hoffmann La Roche Adenosine receptor modulators
WO2001083460A1 (en) 2000-04-28 2001-11-08 Tanabe Seiyaku Co., Ltd. Cyclic compounds
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
DE60142236D1 (de) * 2000-07-24 2010-07-08 Krenitsky Pharmaceuticals Inc Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
EP1474401A2 (en) * 2002-02-05 2004-11-10 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
JP5121707B2 (ja) 2005-07-04 2013-01-16 ハイ ポイント ファーマシューティカルズ，エルエルシー 新規医薬
JP2009537596A (ja) 2006-05-23 2009-10-29 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ６−（４−シクロプロピルピペリジン−１−イル）−２’−メチル−［３，４’］−ビピリジン及びその医薬としての使用
SI2079732T1 (sl) 2006-05-29 2012-03-30 High Point Pharmaceuticals Llc benzodioksol il ciklopropilpiperazin il piridazin njegove soli in solvati in njegova uporaba kot antagonist histaminskega receptorja H
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
ES2923760T3 (es) 2011-06-10 2022-09-30 Merck Patent Gmbh Composiciones y métodos para la producción de compuestos de pirimidina y piridina con actividad inhibidora de BTK
JP6523303B2 (ja) 2014-01-17 2019-05-29 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
RU2021106500A (ru) 2016-06-14 2021-04-16 Новартис Аг Соединения и композиции для подавления активности shp2
AU2018207464B2 (en) 2017-01-10 2020-05-14 Novartis Ag Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (es) *
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
AU680252B2 (en) 1997-07-24
DK0459819T3 (da) 1996-09-02
PT97827B (pt) 1998-10-30
IL98330A (en) 1996-10-31
GR3021237T3 (en) 1997-01-31
PL170373B1 (pl) 1996-12-31
PL166656B1 (pl) 1995-06-30
RU2091374C1 (ru) 1997-09-27
PT97827A (pt) 1992-03-31
FI912623A0 (fi) 1991-05-31
EP0459819A2 (en) 1991-12-04
AU6745594A (en) 1994-09-15
AU7809791A (en) 1991-12-05
CA2043640A1 (en) 1991-12-02
ATE141263T1 (de) 1996-08-15
EP0459819A3 (en) 1992-03-11
KR920000733A (ko) 1992-01-29
IL98330A0 (en) 1992-06-21
JPH06340634A (ja) 1994-12-13
TW224460B (es) 1994-06-01
HU211649A9 (en) 1995-12-28
MY109958A (en) 1997-10-31
IE911861A1 (en) 1991-12-04
NZ238360A (en) 1997-03-24
NZ272001A (en) 1997-03-24
EP0459819B1 (en) 1996-08-14
HU911826D0 (en) 1991-12-30
EP0679645A1 (en) 1995-11-02
DE69121317D1 (de) 1996-09-19
NO912100L (no) 1991-12-02
CS164391A3 (en) 1992-02-19
IL113599A (en) 1997-09-30
AU652753B2 (en) 1994-09-08
NZ248501A (en) 1997-03-24
ZA914165B (en) 1993-03-01
SK278444B6 (en) 1997-05-07
FI912623A7 (fi) 1991-12-02
NO180375B (no) 1996-12-30
CZ281070B6 (cs) 1996-06-12
DE69121317T2 (de) 1997-01-02
GB9012316D0 (en) 1990-07-18
IL113599A0 (en) 1995-08-31
NO912100D0 (no) 1991-05-31
HUT58707A (en) 1992-03-30
NO180375C (no) 1997-04-09
MY136248A (en) 2008-08-29

Similar Documents

Publication Publication Date Title
ES2093078T3 (es) Compuesto farmaceuticamente activo sobre el snc.
NO307047B1 (no) Nye hydroksyetylaminosulfonamider som er nyttige som retrovirale proteasehemmere, farmasøytisk preparat inneholdende slike, og anvendelse derav
ES2040234T3 (es) Derivados del tetrahidronaftaleno y medicamentos que los contienen.
ES2095842T3 (es) Compuestos farmacologicamente activos sobre el snc
CO4290353A1 (es) Agonistas de estrogeno
ES2075121T3 (es) Nuevos compuestos triciclicos.
GT199900150A (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas.
ES2121896T3 (es) Derivados de acido hidroxamico como inhibidores de colagenasa.
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
ES2118710T3 (es) Nuevos inhibidores de peptidasa.
AR240932A2 (es) "composicion para la proteccion de las plantas de cultivo conttra las acciones nocivas de productos quimicos agresivos, compuestos para uso exclusivo en dicha composicion y un procedimiento para preparar dichos compuestos"
MX9300735A (es) Derivados de bencimidazolilo, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
ATE256130T1 (de) Gefässverengende dihydrobenzopyranderivate
ES2065701T3 (es) Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas.
AR018139A1 (es) Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.
ES2067874T3 (es) Derivados de acetamida.
ES2077399T3 (es) Derivados de poli-4-aminopirrol-2-carboxiamida, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES2104841T3 (es) Fosfono-aminoacidos bencimidazolicos.
ES2040363T3 (es) Procedimiento para la obtencion de derivados aromaticos.
ES8705453A1 (es) Un procedimiento para la preparacion de derivados de cefalosporina.
MX9305510A (es) Compuestos para el tratamiento o profilaxis de desordenes gastrointestinales, cardiovasculares y del sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
ES2070002T3 (es) Composiciones terapeuticas a base de derivados de 1,2-ditiol-3-tiona.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
ES2115053T3 (es) Derivados indolicos inhibidores de la 5alfa-reductasa de esteroides.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 459819

Country of ref document: ES